Preliminary studies on the fate of 14C-fentiazac in man.
The disposition of the anti-inflammatory drug fentiazac has been investigated in male volunteers after oral administration of single 200 mg doses of the 14C-labelled compound. Excretion took place predominantly via the faeces with approx. 67% of the dose being recovered in the 0-5 d collection. Urinary excretion accounted for a further 18%, most of which was excreted in the first 24 h. Examination of urinary extracts before and after treatment with beta-glucuronidase showed a relatively simple pattern of metabolites, the major excretion product being a conjugate of p-hydroxyfentiazac. No conjugated material was found in faeces. The major components were p-hydroxyfentiazac and fentiazac itself, in a ratio of 3:2; a minor metabolite was also present, accounting for 10% of the faecal radioactivity.
D000085:Acetates / Q000008:administration & dosage / Q000378:metabolism*; D000284:Administration, Oral; D000328:Adult; D000893:Anti-Inflammatory Agents / Q000378:metabolism; D001711:Biotransformation; D055598:Chemical Phenomena; D002621:Chemistry; D006801:Humans; D008297:Male; D008657:Metabolic Clearance Rate; D013844:Thiazoles / Q000008:administration & dosage / Q000378:metabolism*
D000085:Acetates; D000893:Anti-Inflammatory Agents; D013844:Thiazoles; C006124:fentiazac